Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain
Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.
You may also be interested in...
Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.